Gene Therapy for Rare Disorders Panel Summary
Recently, Precision ADVANCE’s Anshul Mangal moderated “Considerations for Early-Stage Gene Therapy Start-Ups: From Clinical Development to Manufacturing to Commercialization,” at the Gene Therapy for Rare Disorders virtual conference.
Precision ADVANCE Company Presentation: Meeting on the Med
At the recent 2021 Meeting on the Med Conference, CEO & Co-Founder of Precision Medicine Group Mark Clein gave an informative presentation highlighting Precision ADVANCE, the cell & gene therapy collective™, and how it aligns with our mission to bring life-changing therapies to those that need them the most.
Upcoming Webinar: Continuing the Conversation-The Future of Reimbursement for Cell and Gene Therapies
Expanding upon his presentation at the recent World EPA Congress, moderator Richard Macaulay and Precision Value & Health have assembled a unique panel of payers from UK, Germany, and Italy, plus experts within Precision to address how innovative reimbursement strategies for cell and gene therapies (C>s) will evolve.
Conference Video: Virtual ISPOR 2021
Congratulations to Richard Macaulay on his well-attended presentation “The New SMC-Ultra-Orphan Pathway: HTA Best Practice for Very Rare Diseases?” at Virtual ISPOR 2021. Did you miss Richard’s presentation?
Meeting on the Med 2021 Conference Panel: “Innovation: Shortening the Path to Commercialization in Advanced Therapies”
Clare Sarvary Fourrier, SVP of Operational Strategy (EU) for Precision for Medicine moderates this panel discussion with industry experts to share perspectives on the current state of the cell and gene therapy industry and provide key insights in shortening time-to-market for advanced therapies.